All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
BOGOTA, Colombia – Novartis AG is working against the clock in Colombia in a bid to prevent the Colombian government from issuing a mandatory license for the blockbuster cancer drug Glivec (imatinib).
